伴有胸腺瘤的重症肌无力患者环磷酰胺治疗的疗效评价.pdfVIP

III the comparing group, invasion high into divided were hybrid B3 、B2 and hybrid B2 、B1B3,typeB2,typegroup,invasionlow intodividedwereABtypeand B1typeA, type So tumors.malignant and benign thedistinguish to standardstheof one isinvasion tumor and thymoma, B1type and AB type A, type than aggressive more is thymoma B3type B2,type the that suggest studies retrospectiveof number A gravis. myasthenia of score clinical relative and scores absolute clinical the on based treatment fo effect the Evaluate observed. were RNS and scores absolute gravis myasthenia therapeutic The 10g.total toweek /time 1intravenously 0.8g/ weeks,second /time 2intravenously 0.4g/ week, first the / time 2 0.2g/intravenously CTX with MGT the Treat 2. MG.Ⅳtypewith patients9 ，MG Ⅲtype with patients9 ，MG BⅡtypewithpatients24 ，MGAⅡtypewithpatients 13 ，MG Ⅰtype with patients 6 is study of beginning the at stage Clinical hybrid. B3 、B2 of cases 2and hybrid B2 、B1of cases thymoma,5 B3typeof casesthymoma,10 B2typeof cases thymoma,15 B1typeof cases thymoma,21ABtypeof cases thymoma,4Atypeof cases 5 Including 37.49)months.±is(49.53 duration average and old 11.672)years±(46.29 is eagAverageold.years 78toold years20from ageand ，cases 28female ， scase34male the ，them among ，therapy cyclophosphamidewith treated wereThey August.2013to December 2006fromdepartment neurology hospital generalartillery second PLA thein thymomas with accompanied gravis myasthenia 62of total a chosed study This 1. SubjectsSubjects Subjects Subjects indicators.neurophysiologicalon cyclophospham